Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01855828
Title Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Lajos Pusztai

Her2-receptor positive breast cancer


Paclitaxel + Pertuzumab + Trastuzumab

Cyclophosphamide + Epirubicin + Fluorouracil + Pertuzumab + Trastuzumab

Age Groups: adult
Covered Countries USA

No variant requirements are available.